The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
Hematol Oncol
; 41(3): 578-582, 2023 Aug.
Article
em En
| MEDLINE
| ID: mdl-36043430
ABSTRACT
We hypothesized that ruxolitinib may inhibit the immune checkpoint protein, B7H3; and, thus, investigated its effects on this immune inhibitor using multiple myeloma (MM) cell lines, bone marrow (BM) mononuclear cells from MM patients and human MM LAGλ -1A xenografts. Ruxolitinib reduced B7H3 gene and protein expression and increased IL-2 and CD8 gene expression. These results suggest that ruxolitinib inhibition of B7H3 may restore exhausted T-cell activity in the MM BM tumor microenvironment.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Mieloma Múltiplo
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article